<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912882</url>
  </required_header>
  <id_info>
    <org_study_id>ZSCTC1</org_study_id>
    <nct_id>NCT04912882</nct_id>
  </id_info>
  <brief_title>Prognosis Predicting of CRC Patients Based on Morphology and Molecular Biomaker of CTC</brief_title>
  <official_title>Prognosis Predicting of CRC Patients Based on Morphology and Molecular Biomaker of Circulating Tumor Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Detecting circulating tumor cells from I-IV stage colorectal cancer patients pre-and&#xD;
      post-operatively. Analyzing the morphology and biomarkers of CTCs and builting prognosis&#xD;
      predicting model based on the morphology and biomarkers of CTCs. Verifying the prognosis&#xD;
      model by the survival data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>1 year</time_frame>
    <description>The sensitivity of the predictive based on the number and type of circulating tumor cell</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>1 year</time_frame>
    <description>The specificity of predictive model based on the number and type of circulating tumor cell</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>1 year</time_frame>
    <description>Area under curve of the predictive model</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Circulating Tumor Cell</condition>
  <arm_group>
    <arm_group_label>Training Group</arm_group_label>
    <description>Training group including about 500 patients that be using to building the prognosis model</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation Group</arm_group_label>
    <description>Validation group including about another 500 patients that be using to validating the prognosis model</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Circulating tumor cell</intervention_name>
    <description>detecting circulating tumor cell pre- and post operatively</description>
    <arm_group_label>Training Group</arm_group_label>
    <arm_group_label>Validation Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        I-IV stage colorectal cancer patients with resectable lesion(s) who not receive&#xD;
        preoperative treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80 years;&#xD;
&#xD;
        Histologically proven colorectal carcinoma (TNM stage I-IV)&#xD;
&#xD;
        R0 resection is possible according to preoperative evaluation&#xD;
&#xD;
        Written informed consent for participation in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary tumor or metastases not able to be removed radically&#xD;
&#xD;
        Receiving any preoperative treatment (Including chemotherapy, radiotherapy and target&#xD;
        therapy)&#xD;
&#xD;
        Have other malignant tumors meanwhile&#xD;
&#xD;
        Other previous malignancy within 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Xu</last_name>
    <phone>+8613501984869</phone>
    <email>xujmin@aiiyun.com</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

